Cas no 25842-32-4 (2-(4-Benzylpiperidin-1-yl)ethanamine)

2-(4-Benzylpiperidin-1-yl)ethanamine is a versatile organic compound featuring a benzyl-substituted piperidine core linked to an ethanamine moiety. This structure imparts potential utility as an intermediate in pharmaceutical synthesis, particularly for bioactive molecules targeting central nervous system (CNS) receptors. The benzylpiperidine scaffold is known for its affinity toward neurotransmitter transporters, while the ethanamine tail enhances solubility and offers a functional handle for further derivatization. The compound’s well-defined heterocyclic framework makes it valuable for medicinal chemistry research, enabling the development of ligands with tailored pharmacological properties. Its synthetic accessibility and modular design further support its use in structure-activity relationship (SAR) studies.
2-(4-Benzylpiperidin-1-yl)ethanamine structure
25842-32-4 structure
Product Name:2-(4-Benzylpiperidin-1-yl)ethanamine
CAS No:25842-32-4
MF:C14H22N2
MW:218.337883472443
MDL:MFCD03659719
CID:252239
PubChem ID:2779831
Update Time:2025-09-28

2-(4-Benzylpiperidin-1-yl)ethanamine Chemical and Physical Properties

Names and Identifiers

    • 2-(4-Benzylpiperidin-1-yl)ethanamine
    • 1-(2-AMINOETHYL)-4-BENZYLPIPERIDINE
    • 1-Piperidineethanamine,4-(phenylmethyl)-
    • 2-(4-Benzylpiperidino)-1-ethanamine
    • 2-(4-Benzylpiperdin-1-yl)ethylamine
    • CHEMBL3780926
    • SCHEMBL543919
    • 2-[4-(Phenylmethyl)piperidin-1-Yl]ethanamine
    • 2-(4-benzylpiperidin-1-yl)ethylamine
    • FT-0608584
    • BDBM50158094
    • 2-(4-benzylpiperidin-1-yl)ethan-1-amine
    • 5NR
    • BB 0255077
    • 2-(4-benzyl-piperidin-1-yl)-ethylamine
    • A877460
    • Q27455890
    • MFCD03659719
    • AKOS000266423
    • PCNDXYHWLSHXMV-UHFFFAOYSA-N
    • PS-11154
    • N-(2-aminoethyl)-4-benzylpiperidine
    • DTXSID40381567
    • SB43377
    • 25842-32-4
    • DB-067477
    • ALBB-005695
    • STK500810
    • MDL： MFCD03659719
    • Inchi： 1S/C14H22N2/c15-8-11-16-9-6-14(7-10-16)12-13-4-2-1-3-5-13/h1-5,14H,6-12,15H2
    • InChI Key： PCNDXYHWLSHXMV-UHFFFAOYSA-N
    • SMILES： N1(CCN)CCC(CC2C=CC=CC=2)CC1

Computed Properties

  • Exact Mass: 218.17800
  • Monoisotopic Mass: 218.178
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 2
  • Heavy Atom Count: 16
  • Rotatable Bond Count: 4
  • Complexity: 179
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 29.3A^2
  • XLogP3: 2

Experimental Properties

  • Density: 1.005
  • Boiling Point: 130-131°C 3mm
  • Flash Point: 141.8°C
  • Refractive Index: 1.545
  • PSA: 29.26000
  • LogP: 2.53800

2-(4-Benzylpiperidin-1-yl)ethanamine Security Information

  • Signal Word：warning
  • Hazard Statement： Corrosive
  • Warning Statement： P264+P280+P305+P351+P338+P337+P313
  • Hazardous Material transportation number：UN 2735
  • Hazard Category Code： 34
  • Safety Instruction： S26; S36/37/39
  • Hazardous Material Identification： C Xi
  • HazardClass：IRRITANT
  • Risk Phrases：R34
  • Storage Condition：storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)

2-(4-Benzylpiperidin-1-yl)ethanamine Customs Data

  • HS CODE：2933399090
  • Customs Data：

    China Customs Code:

    2933399090

    Overview:

    2933399090. Other compounds with non fused pyridine rings in structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

    Declaration elements:

    Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date

    Summary:

    2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

2-(4-Benzylpiperidin-1-yl)ethanamine Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Fluorochem
034278-1g
2-(4-Benzylpiperdin-1-yl)ethylamine
 25842-32-4 95%
1g
 ￡93.00 2022-03-01
Fluorochem
034278-2g
2-(4-Benzylpiperdin-1-yl)ethylamine
 25842-32-4 95%
2g
 ￡160.00 2022-03-01
Apollo Scientific
OR25989-1g
2-(4-Benzylpiperidin-1-yl)ethylamine
 25842-32-4
1g
 ￡114.00 2025-02-19
TRC
B704268-50mg
2-(4-benzylpiperidin-1-yl)ethanamine
 25842-32-4
50mg
 $ 50.00 2022-06-06
TRC
B704268-100mg
2-(4-benzylpiperidin-1-yl)ethanamine
 25842-32-4
100mg
 $ 70.00 2022-06-06
TRC
B704268-500mg
2-(4-benzylpiperidin-1-yl)ethanamine
 25842-32-4
500mg
 $ 230.00 2022-06-06
Chemenu
CM304782-1g
2-(4-Benzylpiperidin-1-yl)ethanamine
 25842-32-4 95%
1g
 $329 2021-08-18
Chemenu
CM304782-5g
2-(4-Benzylpiperidin-1-yl)ethanamine
 25842-32-4 95%
5g
 $986 2021-08-18
Chemenu
CM304782-1g
2-(4-Benzylpiperidin-1-yl)ethanamine
 25842-32-4 95%
1g
 $230 2022-09-29
abcr
AB153662-1 g
2-(4-Benzylpiperidino)-1-ethanamine, 95%; .
 25842-32-4 95%
1 g
 €191.10 2023-07-20

2-(4-Benzylpiperidin-1-yl)ethanamine Related Literature

Additional information on 2-(4-Benzylpiperidin-1-yl)ethanamine

Recent Advances in the Study of 2-(4-Benzylpiperidin-1-yl)ethanamine (CAS: 25842-32-4) in Chemical Biology and Pharmaceutical Research

The compound 2-(4-Benzylpiperidin-1-yl)ethanamine (CAS: 25842-32-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, focusing on its synthesis, pharmacological properties, and potential clinical applications. The information presented herein is derived from peer-reviewed academic literature, industry reports, and technical documents published within the last two years.

Recent studies have highlighted the role of 2-(4-Benzylpiperidin-1-yl)ethanamine as a key intermediate in the synthesis of novel bioactive molecules. Its structural features, including the benzylpiperidine moiety and the ethanamine side chain, make it a versatile scaffold for drug development. Researchers have explored its utility in the design of ligands targeting G protein-coupled receptors (GPCRs), which are implicated in a wide range of physiological processes and diseases. Notably, modifications to the ethanamine side chain have been shown to enhance binding affinity and selectivity for specific receptor subtypes.

In addition to its role as a synthetic intermediate, 2-(4-Benzylpiperidin-1-yl)ethanamine has demonstrated promising pharmacological activities in preclinical studies. For instance, recent investigations have revealed its potential as an analgesic agent, with mechanisms of action involving the modulation of opioid receptors. Furthermore, its ability to cross the blood-brain barrier has sparked interest in its application for central nervous system (CNS) disorders, such as neuropathic pain and depression. These findings underscore the compound's therapeutic versatility and warrant further exploration.

The synthesis of 2-(4-Benzylpiperidin-1-yl)ethanamine has also been a focus of recent research, with efforts directed toward optimizing yield and purity. Advanced catalytic methods, including asymmetric hydrogenation and transition metal-catalyzed coupling reactions, have been employed to achieve stereoselective synthesis. These advancements not only improve the efficiency of production but also enable the generation of enantiomerically pure forms, which are critical for evaluating structure-activity relationships (SAR) and minimizing off-target effects.

Despite these promising developments, challenges remain in the clinical translation of 2-(4-Benzylpiperidin-1-yl)ethanamine-based therapeutics. Issues such as metabolic stability, potential toxicity, and formulation optimization need to be addressed through rigorous preclinical and clinical testing. Collaborative efforts between academia and industry will be essential to overcome these hurdles and unlock the full potential of this compound. Future research directions may include the development of prodrug strategies and the exploration of combination therapies to enhance efficacy and safety.

In conclusion, 2-(4-Benzylpiperidin-1-yl)ethanamine (CAS: 25842-32-4) represents a promising candidate for drug development, with applications spanning pain management, CNS disorders, and beyond. The latest research underscores its versatility as a synthetic intermediate and its potential as a therapeutic agent. Continued investigation into its pharmacological properties and optimization of its synthetic routes will be critical for advancing this compound toward clinical use. This briefing serves as a valuable resource for researchers and industry professionals seeking to stay abreast of the latest developments in this rapidly evolving field.

25842-32-4 (2-(4-Benzylpiperidin-1-yl)ethanamine) Related Products

Recommended suppliers
Shanghai Pearlk Chemicals Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jiangxi Boyang Pharmaceutical Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jiangxi Boyang Pharmaceutical Chemical Co., Ltd
Yunnanjiuzhen
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Yunnanjiuzhen
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Amadis Chemical Company Limited
ASIACHEM I&E (JIANGSU) CO., LTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
ASIACHEM I&E (JIANGSU) CO., LTD